Inve India ▾

Eris Lifesciences share price & results

Eris Lifesciences Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Ahmedabad pharma: branded chronic-therapy drugs domestically, 6 plants making injectables and biologics.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue482 ₹ crore−25.8% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin38.0 %−8.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit129 ₹ crore−14.0% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity18.04 %+5.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin7.70 %−23.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)11.08 %−35.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

1 of 9 judged targets kept · 18 open · verdicts reflect calls analysed to Q1 FY27.

Eris Lifesciences Limited management guidance track record on Inve: 27 targets tracked across analysed earnings calls (1 achieved, 8 missed, 18 open).

TargetOriginal wordingSaidLatest callVerdict
Consolidated EBITDA Margin35% for FY25
Call transcript, Q2 FY25 · 25 Oct 2024		Q2 FY25Q1 FY27:Target period passed.
Call transcript, Q1 FY27 · 29 Jul 2026		Achieved
DBF Revenue₹2,600 crores for FY25
Call transcript, Q2 FY25 · 25 Oct 2024		Q2 FY25Q1 FY27:Target period passed.
Call transcript, Q1 FY27 · 29 Jul 2026		Missed
CDMO Revenue₹100 crores revenue for FY27
Call transcript, Q1 FY26 · 5 Aug 2025		Q1 FY26Q1 FY27:Management states CAPA actions for EU GMP are on track for sites to be audit-ready by Dec 2026. However, FY27 export guidance is now 'flattish', reinforcing the significant risk to this revenue target.
Call transcript, Q1 FY27 · 29 Jul 2026		At Risk

Source: Inve Guidance Tracker for Eris Lifesciences Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

8 of Eris Lifesciences Limited's 27 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 24 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,105.2 +0.89% · +₹9.7

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −30.2% 1Y

₹1.2k₹1.4k₹1.6kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 12 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 29 Jul 2026

1Y: ₹1,582.6 on 24 Oct 2025 → ₹1,105.2. High ₹1,701.3 (9 Dec 2025), low ₹1,095.5 (23 Oct 2026).

Previous close
₹1,095.5
Market cap
₹15.3k Cr
52-week range
₹1,095.5 – ₹1,701.3
One year
−32.10%
Price to earnings (TTM to Sept 2026)
20.51×
Return on equity (TTM to Sept 2026)
18.04%

Overview

Symbol
NSE:ERIS
Exchange
NSE
Currency
INR

What Eris Lifesciences Limited does

Based on the company's own presentations, annual report and earnings calls.

Eris Lifesciences is an Indian pharmaceutical company that sells branded prescription formulations to doctors and patients through the domestic market, earning the bulk of its revenue from chronic and sub-chronic therapies such as oral anti-diabetes, cardiovascular disease and vitamins/minerals/nutrition (VMN), alongside emerging specialties like dermatology, insulins, women's health, CNS, critical care, nephrology and oncology. It has vertically integrated backward into manufacturing across small-molecule oral solids/liquids, sterile injectables and biologics (insulins, GLP-1 analogues, monoclonal antibodies), largely built through acquisitions (Biocon's India branded-formulations business, Swiss Parenterals, Eris BioNxt, a stake in Levim Lifetech). It is also building an international arm, exporting from its Swiss Parenterals and Ahmedabad sites and pursuing a Europe-focused CDMO business.

Segments

  • Domestic Branded Formulations (DBF)
  • International Business
Manufacturing units
6 globally accredited/compliant units across 4 states (Ahmedabad x3, Guwahati, Raisen/Bhopal MP, Chennai)
IPM market rank
Ranked 20th in the Indian Pharmaceutical Market (IPM); youngest company among the Top-20
Therapy areas
Oral Anti-Diabetes, Insulins, Cardiovascular, VMN, Dermatology, Women's Health, CNS, Critical Care, Nephrology, Oncology
Mother brand portfolio
Top-25 mother brands, 15 of which rank in the Top-5 of their respective segments
Prescription rank (Dermatologists)
#2 nationally
Prescription rank (Diabetologists/Endocrinologists)
#5 nationally
Founded 2007Headquarters Ahmedabad, Gujarat Company website

How the price took the results

close before → close after

Q1 FY27
+2.6%
29 Jul
Q4 FY26
+9.1%
20 May
Q3 FY26
−6.4%
13 Feb
Q2 FY26
−1.3%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Eris Lifesciences Limited

Free account: one company. Everything above stays public.

Write why you follow Eris Lifesciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Eris Lifesciences Limited

Guides on how to read this kind of business and the numbers that matter.